Pembrolizumab biosimilar (Xbrane Biopharma)

帕博利珠单抗生物类似药（Xbrane Biopharma）

Report date: 2025/02/19 10:32:23

Base Information

Drug NamePembrolizumab biosimilar (Xbrane Biopharma)
Drug Alias NameXtrudane
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesXbrane Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXbrane Biopharma Ab
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A